CD4 and non-small cell lung carcinoma: Our previous study indicated that the higher level of baseline CD16+CD56+ NK cell counts and the ratio of CD4+/CD8+ T cells in peripheral blood could predict longer progression free survival (PFS) and better response in NSCLC patients treated with anti-PD-1 based therapy [26].